CY1117165T1 - Καινοφανεις τρικυκλικες ενωσεις - Google Patents

Καινοφανεις τρικυκλικες ενωσεις

Info

Publication number
CY1117165T1
CY1117165T1 CY20161100074T CY161100074T CY1117165T1 CY 1117165 T1 CY1117165 T1 CY 1117165T1 CY 20161100074 T CY20161100074 T CY 20161100074T CY 161100074 T CY161100074 T CY 161100074T CY 1117165 T1 CY1117165 T1 CY 1117165T1
Authority
CY
Cyprus
Prior art keywords
compounds
new tricycle
new
tricycle compounds
prodrugs
Prior art date
Application number
CY20161100074T
Other languages
Greek (el)
English (en)
Inventor
Neil Wishart
Maria A Argiriadi
David J Calderwood
Anna M Ericsson
Bryan A Fiamengo
Kristine E Frank
Michael Friedman
Dawn M George
Eric R Goedken
Nathan S Josephsohn
Biqin C Li
Michael J Morytko
Kent D Stewart
Jeffrey W Voss
Grier A Wallace
Lu Wang
Kevin R Woller
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41415363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117165(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of CY1117165T1 publication Critical patent/CY1117165T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
CY20161100074T 2008-06-10 2016-01-27 Καινοφανεις τρικυκλικες ενωσεις CY1117165T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13160208P 2008-06-10 2008-06-10
US13159908P 2008-06-10 2008-06-10
US19015908P 2008-08-26 2008-08-26
US20106408P 2008-12-05 2008-12-05
EP09763424.0A EP2299821B1 (en) 2008-06-10 2009-06-09 Tricyclic compounds

Publications (1)

Publication Number Publication Date
CY1117165T1 true CY1117165T1 (el) 2017-04-05

Family

ID=41415363

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100074T CY1117165T1 (el) 2008-06-10 2016-01-27 Καινοφανεις τρικυκλικες ενωσεις

Country Status (36)

Country Link
US (5) US8962629B2 (enExample)
EP (2) EP3031324A3 (enExample)
JP (2) JP5748659B2 (enExample)
KR (2) KR101718384B1 (enExample)
CN (2) CN104592231A (enExample)
AR (1) AR072086A1 (enExample)
AU (1) AU2009257602B2 (enExample)
BR (1) BRPI0915374B1 (enExample)
CA (2) CA3000973A1 (enExample)
CL (1) CL2010001426A1 (enExample)
CO (1) CO6382083A2 (enExample)
CR (1) CR20160007A (enExample)
CY (1) CY1117165T1 (enExample)
DK (1) DK2299821T3 (enExample)
DO (2) DOP2010000382A (enExample)
EC (1) ECSP10010657A (enExample)
ES (1) ES2559403T3 (enExample)
HR (1) HRP20160098T1 (enExample)
HU (1) HUE028347T2 (enExample)
IL (1) IL209434A0 (enExample)
ME (1) ME02340B (enExample)
MX (1) MX2010013557A (enExample)
MY (1) MY161369A (enExample)
NO (1) NO20101688A1 (enExample)
NZ (1) NZ623922A (enExample)
PE (2) PE20110223A1 (enExample)
PL (1) PL2299821T3 (enExample)
PT (1) PT2299821E (enExample)
RS (1) RS54560B1 (enExample)
RU (2) RU2015105591A (enExample)
SI (1) SI2299821T1 (enExample)
TW (3) TWI449703B (enExample)
UA (1) UA106045C2 (enExample)
UY (1) UY31881A (enExample)
WO (1) WO2009152133A1 (enExample)
ZA (1) ZA201008562B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3000973A1 (en) 2008-06-10 2009-12-17 Abbvie Inc. Tricyclic compounds
US20120034250A1 (en) * 2009-04-14 2012-02-09 Astellas Pharma Inc. Condensed pyrrolopyridine derivative
ES2552805T3 (es) 2009-04-20 2015-12-02 Auspex Pharmaceuticals, Llc Inhibidores piperidínicos de la cinasa Janus 3
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
US8361962B2 (en) * 2009-07-27 2013-01-29 Roche Palo Alto Llc Tricyclic inhibitors of JAK
EP2475667A1 (en) 2009-09-10 2012-07-18 F. Hoffmann-La Roche AG Inhibitors of jak
ES2509590T3 (es) 2009-09-21 2014-10-17 F. Hoffmann-La Roche Ag Inhibidores macrocíclicos de JAK
KR20130036171A (ko) 2009-10-29 2013-04-11 브리스톨-마이어스 스큅 컴퍼니 트리시클릭 헤테로시클릭 화합물
MX2012006381A (es) * 2009-12-01 2012-06-19 Abbott Lab Nuevos compuestos triciclicos.
TW201802091A (zh) 2009-12-01 2018-01-16 艾伯維有限公司 新穎三環化合物
US8329705B2 (en) 2009-12-30 2012-12-11 Arqule, Inc. Substituted triazolo-pyrazine compounds
CN102712640A (zh) * 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 三环杂环化合物、其组合物和应用方法
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
DE102011106849A1 (de) * 2010-12-15 2012-06-21 Merck Patent Gmbh Verfahren zur Synthese N-N verknüpfter und um die N-N Bindung rotationsgehinderter bis-N-heterocyclische Carbene und deren Einsatz als Liganden für Metallkomplexe
TW201309639A (zh) * 2011-02-17 2013-03-01 Lg Life Sciences Ltd 作為ｇｐｒ１１９促效劑之肟衍生物
WO2012127506A1 (en) * 2011-03-22 2012-09-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
SG194216A1 (en) * 2011-04-21 2013-11-29 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
WO2012149280A2 (en) * 2011-04-29 2012-11-01 Abbott Laboratories Novel tricyclic compounds
AR086113A1 (es) 2011-04-30 2013-11-20 Abbott Lab Isoxazolinas como agentes terapeuticos
WO2013007768A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
RU2632870C2 (ru) 2011-08-12 2017-10-11 Ниссан Кемикал Индастриз, Лтд. Трициклические гетероциклические соединения и ингибиторы jak
JP6220786B2 (ja) 2012-07-19 2017-10-25 大日本住友製薬株式会社 １−（シクロアルキルカルボニル）プロリン誘導体
HK1206728A1 (en) 2012-09-17 2016-01-15 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
IN2015DN02008A (enExample) * 2012-09-21 2015-08-14 Advinus Therapeutics Ltd
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
CN102961382B (zh) * 2012-11-28 2014-07-16 玉林师范学院 一种骨肉瘤细胞抑制剂及制备方法
WO2014123167A1 (ja) 2013-02-08 2014-08-14 日産化学工業株式会社 ３環性ピロロピリジン化合物及びｊａｋ阻害剤
JP2016135742A (ja) * 2013-03-29 2016-07-28 日本農薬株式会社 縮合複素環化合物又はその塩類及び該化合物を含有する農園芸用殺虫剤並びにその使用方法
WO2014169473A1 (en) * 2013-04-19 2014-10-23 Abbvie Inc. 6H-IMIDAZO[1,5-a]PYRROLO[2,3-e]PYRAZINE COMPOUNDS
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN103694168B (zh) * 2013-12-05 2015-08-19 贵州威顿晶磷电子材料股份有限公司 一种6-氯-4-三氟甲基-3-氰基吡啶的制备方法
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2944433A1 (en) 2014-05-14 2015-11-19 Nissan Chemical Industries, Ltd. Tricyclic compound and jak inhibitor
ES2809458T3 (es) 2014-07-17 2021-03-04 Pharmaceutical Manufacturing Res Services Inc Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata
EP3185852A1 (en) * 2014-08-27 2017-07-05 AbbVie Inc. Topical formulation
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10457677B2 (en) 2015-04-02 2019-10-29 Merck Patent Gmbh Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN120478294A (zh) 2015-10-16 2025-08-15 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
MD3419978T2 (ro) 2016-02-24 2020-07-31 Pfizer Derivaţi de pirazolo[1,5-a]pirazin-4-il
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
RS63500B1 (sr) 2016-12-16 2022-09-30 Janssen Pharmaceutica Nv Jedinjenja imidazo[4,5-d]pirolo[2,3-b]piridina kao inhibitori janus kinaza
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
AU2018230500B2 (en) 2017-03-09 2024-03-07 Abbvie Inc. Methods of treating Crohn's disease and ulcerative colitis
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2019034973A1 (en) 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
US11512067B2 (en) 2017-09-14 2022-11-29 Daiichi Sankyo Company, Limited Compound having cyclic structure
WO2019100008A1 (en) * 2017-11-20 2019-05-23 Georgetown University Treatments and methods for controlling hypertension
MX2020007010A (es) 2018-01-05 2020-12-10 Ottawa Hospital Res Inst Vectores modificados de orthopoxvirus.
UY38144A (es) 2018-03-12 2019-10-31 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa
CN110294761B (zh) * 2018-06-08 2020-09-08 南京雷正医药科技有限公司 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
CN110872250B (zh) * 2018-08-31 2023-01-10 苏州鹏旭医药科技有限公司 两种化合物及其制备方法和在合成乌西替尼中的用途
EP4520395A3 (en) 2018-11-01 2025-05-21 Lynk Pharmaceuticals Co. Ltd. Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN109369659B (zh) * 2018-12-06 2020-10-27 浙江师范大学 一种jak抑制剂的合成方法
EP4006028B1 (en) * 2019-07-26 2025-07-02 Zhuhai Yufan Biotechnologies Co., Ltd Irak4 kinase inhibitor and preparation method therefor
CN110483514B (zh) * 2019-09-16 2022-06-14 启元生物(杭州)有限公司 一种氰基取代的环肼衍生物及其应用
CN113912535B (zh) * 2020-07-07 2023-04-07 新发药业有限公司 一种6-氯-4-三氟甲基-3-氰基吡啶的制备方法
CA3189037A1 (en) 2020-07-08 2022-01-13 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of upadacitinib, preparation method therefor, and use thereof
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CN112028888B (zh) * 2020-09-11 2021-08-20 中国药科大学 一种化合物及其制备方法和用途
US20240108633A1 (en) * 2020-12-29 2024-04-04 Onquality Pharmaceuticals China Ltd. Method for preventing or treating disease or condition associated with antitumor agent
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN113332298A (zh) * 2021-05-27 2021-09-03 成都医学院 米诺环素作为酪氨酸激酶抑制剂的新用途
CN113603693B (zh) * 2021-07-13 2022-08-26 陕西丽彩药业有限公司 一种2-溴-5-对甲苯磺酰基-5H-吡咯并[2,3-b]吡嗪的制备方法
WO2023194842A1 (en) 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in rheumatoid arthritis
CN116947750A (zh) * 2023-06-28 2023-10-27 北京民康百草医药科技有限公司 一种奈妥匹坦关键杂质的制备方法及检测方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1376A (en) * 1839-10-18 Wateb-wheel
GB716327A (en) 1951-09-05 1954-10-06 Ici Ltd New heterocyclic compounds
US3663559A (en) * 1969-12-03 1972-05-16 Union Carbide Corp Preparation of oxo-furo-pyridines from furylvinyl isocyanates
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4053474A (en) * 1976-04-21 1977-10-11 E. R. Squibb & Sons, Inc. Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
CA2028235C (en) 1989-10-20 1997-01-21 Fumio Suzuki Condensed purine derivatives
DE69133405T2 (de) 1990-01-11 2005-07-07 Isis Pharmaceutical, Inc., Carlsbad Oligonukleotidderivate zur detektieren und modulation von rna aktivität und genexpression
US6262241B1 (en) * 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
EP1905782A1 (en) 1991-03-18 2008-04-02 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
CA2110942A1 (en) 1991-06-14 1992-12-23 Pharmacia & Upjohn Company Llc Imidazo¬1,5-a|quinoxalines
US5212310A (en) * 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5266698A (en) * 1992-04-30 1993-11-30 Neurogen Corporation Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
US5306819A (en) 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
CN1118600A (zh) 1993-02-26 1996-03-13 先灵公司 2-苄基-多环鸟嘌呤衍生物以及制备它们的方法
US5736540A (en) * 1993-07-29 1998-04-07 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5733905A (en) * 1993-07-29 1998-03-31 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
RU2158127C2 (ru) 1994-12-23 2000-10-27 Варнер-Ламберт Компани Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция
US5521173A (en) * 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5763137A (en) * 1995-08-04 1998-06-09 Agfa-Gevaert, N.V. Method for making a lithographic printing plate
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO1999045009A1 (en) * 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
TWI271406B (en) * 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
MXPA03001186A (es) * 2000-08-07 2004-04-20 Neurogen Corp Compuestos heterociclicos como ligandos del receptor acido gamma aminobutirico (gabaa).
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
ATE353013T1 (de) * 2002-02-19 2007-02-15 Pfizer Italia Srl Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US7169926B1 (en) * 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20060074102A1 (en) * 2004-05-14 2006-04-06 Kevin Cusack Kinase inhibitors as therapeutic agents
PE20060526A1 (es) * 2004-06-15 2006-07-13 Schering Corp Compuestos triciclicos como antagonistas de mglur1
EP1773840B1 (de) 2004-07-23 2010-01-20 The Medicines Company (Leipzig) GmbH Substituierte pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und pyrido[3',2':4,5]furo[3,2-d]-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
WO2006074985A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
EP1844048B1 (en) 2005-01-14 2010-05-26 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
AU2006232294A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
US7593820B2 (en) * 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
CA2615291A1 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
EP1919924A2 (en) * 2005-08-16 2008-05-14 Irm, Llc Compounds and compositions as protein kinase inhibitors
JP4551962B2 (ja) 2005-09-23 2010-09-29 コーリー ファーマシューティカル グループ，インコーポレイテッド １Ｈ−イミダゾ［４，５−ｃ］ピリジンおよびその類似体のための方法
EP1954290B1 (en) 2005-11-22 2012-07-25 Merck Sharp & Dohme Corp. Tricyclic compounds useful as inhibitors of kinases
JP5512975B2 (ja) * 2005-12-29 2014-06-04 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CA2665214A1 (en) 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
US20100105661A1 (en) 2007-01-12 2010-04-29 Astellas Pharma Inc. Condensed pyridine compound
US20110281821A9 (en) 2007-01-30 2011-11-17 Biogen Idec Ma Inc. Modulators of Mitotic Kinases
WO2008112695A2 (en) 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
US7723343B2 (en) 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
AU2009218607B2 (en) * 2008-02-25 2014-02-13 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
EP2247595B1 (en) * 2008-02-25 2011-07-20 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
CN101952294B (zh) * 2008-02-25 2014-11-26 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
WO2009108827A1 (en) 2008-02-29 2009-09-03 Wyeth Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
CA3000973A1 (en) 2008-06-10 2009-12-17 Abbvie Inc. Tricyclic compounds
CN102143746A (zh) 2008-07-03 2011-08-03 埃克塞利希斯股份有限公司 Cdk 调节剂
US20120034250A1 (en) * 2009-04-14 2012-02-09 Astellas Pharma Inc. Condensed pyrrolopyridine derivative
US8361962B2 (en) * 2009-07-27 2013-01-29 Roche Palo Alto Llc Tricyclic inhibitors of JAK
TW201802091A (zh) * 2009-12-01 2018-01-16 艾伯維有限公司 新穎三環化合物
MX2012006381A (es) 2009-12-01 2012-06-19 Abbott Lab Nuevos compuestos triciclicos.
WO2011156698A2 (en) * 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
WO2012149280A2 (en) * 2011-04-29 2012-11-01 Abbott Laboratories Novel tricyclic compounds
WO2013043826A1 (en) * 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors

Also Published As

Publication number Publication date
ECSP10010657A (es) 2011-02-28
CA2727032C (en) 2018-08-14
TW201434841A (zh) 2014-09-16
IL209434A0 (en) 2011-01-31
KR101718384B1 (ko) 2017-03-22
SI2299821T1 (sl) 2016-03-31
US20230082167A1 (en) 2023-03-16
US20090312338A1 (en) 2009-12-17
HK1155617A1 (zh) 2012-05-25
TW201002720A (en) 2010-01-16
UA106045C2 (uk) 2014-07-25
CN104592231A (zh) 2015-05-06
RU2545023C2 (ru) 2015-03-27
CN102118968A (zh) 2011-07-06
CL2010001426A1 (es) 2011-07-15
TW201612182A (en) 2016-04-01
US9365579B2 (en) 2016-06-14
CO6382083A2 (es) 2012-02-15
CR20160007A (es) 2016-03-15
MY161369A (en) 2017-04-14
ME02340B (me) 2017-02-20
AU2009257602A1 (en) 2009-12-17
HRP20160098T1 (hr) 2016-02-26
EP2299821A4 (en) 2012-02-08
PE20110223A1 (es) 2011-05-07
AR072086A1 (es) 2010-08-04
RU2015105591A (ru) 2015-08-10
UY31881A (es) 2010-01-29
US20160326181A1 (en) 2016-11-10
HUE028347T2 (en) 2016-12-28
RU2010153582A (ru) 2012-07-20
BRPI0915374A2 (pt) 2015-08-04
ZA201008562B (en) 2012-05-30
RU2015105591A3 (enExample) 2018-10-10
WO2009152133A1 (en) 2009-12-17
CA3000973A1 (en) 2009-12-17
PE20140407A1 (es) 2014-04-25
RU2545023C9 (ru) 2016-06-20
DK2299821T3 (en) 2016-02-15
US20180291029A1 (en) 2018-10-11
EP2299821A1 (en) 2011-03-30
TWI449703B (zh) 2014-08-21
JP2012505152A (ja) 2012-03-01
RS54560B1 (sr) 2016-06-30
JP2015163632A (ja) 2015-09-10
BRPI0915374B1 (pt) 2021-05-25
EP2299821B1 (en) 2015-11-04
NO20101688A1 (no) 2011-03-09
EP3031324A2 (en) 2016-06-15
EP3031324A3 (en) 2016-09-07
DOP2013000055A (es) 2013-04-30
US20150210708A1 (en) 2015-07-30
KR20160148053A (ko) 2016-12-23
TWI527819B (zh) 2016-04-01
DOP2010000382A (es) 2018-06-30
PL2299821T3 (pl) 2016-05-31
ES2559403T3 (es) 2016-02-12
KR20110017431A (ko) 2011-02-21
NZ623922A (en) 2015-09-25
AU2009257602B2 (en) 2015-10-08
MX2010013557A (es) 2011-03-24
US8962629B2 (en) 2015-02-24
PT2299821E (pt) 2016-03-11
JP5748659B2 (ja) 2015-07-15
CA2727032A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
CY1117165T1 (el) Καινοφανεις τρικυκλικες ενωσεις
CY1119175T1 (el) Καινοτομες τρικυκλικες ενωσεις
DOP2012000149A (es) Compuestos triciclicos novedosos
CY1123705T1 (el) Αλατα και πολυμορφα μιας ενωσης τετρακυκλινης
CY1118650T1 (el) Παραγωγα βενζιμιδαζολιου
CY1118993T1 (el) Υποκατεστημενες ενωσεις τετραϋδροϊσοκινολινης ως αναστολεις τελεστη xiα
CY1111166T1 (el) Νεα παραγωγα 1,4-βενζοθειεπινο-1,1-διοξειδιου υποκατεστημενα με ριζες βενζυλιου, μεθοδοι διεργασιων για την παρασκευη τους, φαρμακα που περιεχουν αυτες τις ενωσεις και η χρηση τους
CR20110684A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
HRP20120323T1 (en) Diarylhydantoin compounds
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
CR11036A (es) Derivados y composiciones de isoindol 4' -o- sustituidos, composiciones que las comprenden y metodos de uso de los mismos
NO20080391L (no) Pyrazolbaserte LXR modulatorer
CY1118128T1 (el) Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2
CR9866A (es) Novedosos derivados de 1-aza-bicicloalquilo para el tratamiento de trastornos psicoticos y neurodegenerativos
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
CU20100252A7 (es) Derivados de dibenzotiazepina
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
AR073708A1 (es) Compuestos intermediarios de tiazolil -pirazolopirimidina y procesos sinteticos que los incluyen
GT200800296A (es) Derivados de ácido fenilacético
CY1114798T1 (el) Ενωσεις σουλφοναμιδιου για τη θεραπευτικη αντιμετωπιση αναπνευστικων διαταραχων
EA200901085A1 (ru) Производные циклогексиламида арилкарбоновой кислоты
CY1105699T1 (el) Νεες φαρμακευτικες ενωσεις με αλφα2υποδοχεα δραστηριοτητας